Group 1: Industry Trends - The aging population and the rise of chronic diseases in China, along with comprehensive health insurance coverage, will continue to create challenges in accessing affordable healthcare services [2] - The private healthcare sector has significant growth potential due to these trends, prompting the company to increase investments and acquisitions in the medical service field [3] Group 2: Company Hospital Overview - Key hospitals under the company include Dalian Wasan Hospital, Xuyi Hospital, Liaoyu Hospital, Ganxi Hospital, and Guang'an Fuyuan Hospital, all of which focus on patient-centered and responsible service [3] - Some hospitals have established a strong local reputation, particularly Wasa Hospital in neurology and neurosurgery, and Liaoyu Hospital in obstetrics and gynecology [3] Group 3: Future Development in Medical Services - The company adheres to a "specialized and comprehensive" approach, expanding medical service scale through both external acquisitions and internal development [3] - Future acquisitions will target profitable medical service entities, while internal efforts will enhance existing departments, particularly in oncology and high-end obstetrics [3] Group 4: Precision Medicine and Pharmaceutical Strategy - The company has acquired Shanghai Jieao Paisi to leverage its advantages in genetic testing, enhancing service offerings across its hospitals [4] - The pharmaceutical segment focuses on the "Duyiwei" series of traditional Chinese medicine and chemical drugs, with plans to adjust sales strategies based on local market conditions to maintain steady growth [4] - The health product market, primarily targeting the mid-to-high-end segment, presents significant future growth opportunities [4]

Group 1: Regulatory Issues - The company received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) due to suspected violations of securities laws, leading to a formal investigation [2] - The company has fulfilled its disclosure obligations and has not yet received conclusive opinions from relevant authorities [2] Group 2: Management Changes - Several executives, including former Chairman Que Wenbin, have left the company, which some speculate is related to the strategic shift from pharmaceuticals to healthcare services [2] - The departure of these executives represents a small percentage of the overall management team, and the company believes it will not adversely affect daily operations [2] Group 3: Financial Performance - In the first half of the year, sales expenses increased by 334.40%, primarily due to increased costs associated with drug and toothpaste sales [3] - The increase in sales expenses is attributed to a low base from the previous year and adjustments in sales policies due to new pharmaceutical regulations [3] Group 4: Hospital Performance - The company has experienced rapid growth in its medical services sector, but some previously acquired hospitals are facing stagnation in organic growth [2] - To address this, the company plans to enhance hospital services through hardware upgrades and software improvements, including the introduction of advanced medical technologies and the establishment of a shared platform for its hospitals [2]

Group 1: Financial Performance - The company reported significant growth in both revenue and net profit for the first half of 2016, attributed to an expanded consolidation scope including hospitals like Wasan, Xuyi, and Fuyuan [2] - The gross profit margin in key regions (Northeast, East China, and Southwest) showed a decline, primarily due to increased investments in talent and discipline construction [2] Group 2: Strategic Planning - The company’s strategy focuses on a "big specialty, strong comprehensive" approach, emphasizing cancer treatment and high-end obstetrics and gynecology [2] - The acquisition of Chongzhou Second Hospital was completed in early September 2016, with intentions to expand further into regions like Lankao and Siyang [2] Group 3: Hospital Management and Expansion - The company currently controls 10 hospitals and has 4 under construction, with a focus on hospitals with significant specialty advantages and a population of over 600,000 in the region [2] - The company aims to leverage synergies among its hospitals through advanced management platforms and data integration [3] Group 4: Market Position and Future Outlook - The private healthcare market in China is on the rise, with significant potential for differentiation from public hospitals through flexibility in operations and service quality [4] - The company believes that the "drug-based medical funding" model will evolve, leading to a healthier and more dynamic healthcare environment [4]

Group 1: Financial Performance - The company experienced significant growth in both revenue and net profit in the first half of 2016, attributed to the expansion of the consolidated financial statement scope and improved internal management practices [2]. - The company invested CNY 177 million in Chongzhou Second Hospital to enhance its construction, leveraging its strong local brand and reputation [2]. Group 2: Hospital Operations - Ganxi Tumor Hospital has officially commenced operations and is building a solid foundation in brand, business development, and talent, while collaborating with Jiangxi Provincial Tumor Hospital to enhance its local influence [2]. - The company focuses on selecting hospitals that are either restructured or can be restructured, prioritizing those with a minimum of secondary class and clear specialty advantages, as well as a concentrated regional population [2]. Group 3: Future Developments - The company is planning to construct hospitals primarily focused on oncology and high-end obstetrics, including Dalian International Tumor Hospital and Mianyang Aibeier Obstetrics Hospital, while integrating existing hospital teams and attracting external talent [2]. - The company has established a centralized procurement center to enhance its bargaining power and achieve cost reduction and efficiency improvements [3].

Group 1: Company Strategy and Development - The company has established a health strategy centered on medical services since 2013, focusing on oncology diagnosis and treatment, adhering to the "specialized and comprehensive" approach [2] - The company aims to integrate its operations with target hospitals, providing comprehensive support in discipline construction, talent acquisition, and funding [3] Group 2: Competitive Advantages - The company possesses a team of experienced hospital management professionals and has developed a unique hospital management model [3] - The company has a specialized investment team with extensive experience in hospital reform and operations [3] Group 3: Product Development and Sales - The company includes pharmaceuticals, health products, and toothpaste as part of its health strategy, with a focus on traditional Chinese medicine [3] - The company is actively expanding both online and offline sales channels for its unique series of products [3]

编号：2021-01 证券代码：002219 证券简称：*ST 恒康 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------|------------| | | □特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | | | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 | 2020 | 年度网上业 | | 及人员姓名 | 绩说明会的投资 ...

证券代码：002219 证券简称：*ST 恒康 编号：2022-01 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------|----------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 2021 年度网上业 | | 及人员姓名 | 绩说明会的投资者 | | | 时间 2022 | 年 5 月 11 日 | 15:00-17:00 | | | 地点 "全景·路演天下"（ | http://rs.p5w.net ） | | | | | | 上市公司接待人员 姓名 | 先生、财务总监刘军先生、董事会 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥805,193,959.15, representing an increase of 8.18% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥15,462,621.60, a significant increase of 185.56% year-on-year[7] - Basic earnings per share for Q3 2022 were ¥0.0189, reflecting a growth of 456.60% compared to the previous year[7] - Total operating revenue for the current period reached ¥2,326,660,478.27, an increase from ¥2,224,300,970.63 in the previous period, representing a growth of approximately 4.6%[36] - Net profit for the current period was ¥121,283,831.87, a significant recovery from a net loss of ¥57,174,950.52 in the previous period[38] - Basic earnings per share for the current period improved to ¥0.0344, compared to a loss of ¥0.0317 per share in the previous period[38] - The company's total profit for the current period was ¥147,571,758.68, a recovery from a total loss of ¥36,220,327.39 in the previous period[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,502,832,413.37, a decrease of 17.75% from the end of the previous year[7] - As of September 30, 2022, total assets amounted to ¥5,502,832,413.37, a decrease from ¥6,690,205,812.98 at the beginning of the year, representing a decline of approximately 17.7%[29] - Current assets decreased to ¥1,767,932,569.64 from ¥3,023,848,238.36, indicating a reduction of about 41.5%[29] - Total liabilities decreased to ¥3,794,910,476.50 from ¥5,104,155,707.98, reflecting a decline of approximately 25.7%[31] - The company's short-term borrowings significantly decreased from ¥1,274,371,644.23 to ¥99,850,000.00, a reduction of about 92.2%[31] - The company's total equity increased to ¥1,707,921,936.87 from ¥1,586,050,105.00, showing an increase of approximately 7.6%[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥97,923,313.84, down 53.27% year-on-year[7] - Cash flow from operating activities generated a net amount of ¥97,923,313.84, down from ¥209,549,867.80 in the previous period[42] - Cash inflow from operating activities totaled ¥2,332,736,027.28, compared to ¥2,184,543,218.48 in the previous period, reflecting an increase of approximately 6.8%[42] - Cash outflow from operating activities was ¥2,234,812,713.44, up from ¥1,974,993,350.68 in the previous period, indicating an increase of about 13.1%[42] - The net cash flow from financing activities was -1,037,090,264.24, a significant decrease compared to -43,062,707.58 from the previous period[45] - The net increase in cash and cash equivalents was -1,399,542,385.38, contrasting with an increase of 29,689,974.08 previously[45] - The ending balance of cash and cash equivalents was 591,558,206.67, down from 1,991,100,592.05 at the beginning of the period[45] Shareholder Information - Total number of common shareholders at the end of the reporting period was 32,374[20] - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 25.30% of shares, totaling approximately 825.93 million shares[20] Company Changes - The company changed its name from "Hengkang Medical Group Co., LTD" to "New Journey Health Technology Group Co., LTD" effective September 26, 2022[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 3.84%, an increase of 13.39% compared to the previous year[7] - The company received government subsidies totaling ¥6,655,762.71 during the quarter, contributing to its non-operating income[8] - Interest expenses increased by 58.29% to approximately $106.21 million compared to the same period last year[16] - Interest income surged by 1775.60% to approximately $8.28 million due to increased interest from restructured investments[16] - Investment income rose by 237.29% to approximately $11.57 million, attributed to debt forgiveness[16] - Credit impairment losses increased significantly by 2319.25% to approximately $38.91 million, reflecting recoveries from previous disposals[16] - Tax refunds received increased by 367.44% to approximately $2.73 million compared to the previous year[16] - Cash paid for operating activities rose by 31.40% to approximately $388.97 million, driven by restructuring costs[16] - Cash received from the disposal of subsidiaries amounted to approximately $42 million, marking a 100% increase[16] - Cash received from investment activities reached approximately $100 million, reflecting bank wealth management redemptions[16]

Financial Performance - The company's operating revenue for Q1 2022 was ¥698,315,770.31, representing an increase of 8.98% compared to the same period last year[6] - The net profit attributable to shareholders was -¥47,235,805.90, a decline of 102.53% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥29,791,344.38, a decrease of 103.76% compared to the previous year[6] - The net profit for the quarter was ¥2,413,594.74, a significant recovery from a net loss of ¥48,758,930.91 in the same period last year[31] - The net profit attributable to the parent company was CNY 1,193,558.53, a decrease from a net loss of CNY 47,235,805.90 in the previous period[34] - The total comprehensive income attributable to the parent company was CNY 1,193,558.53, compared to a total comprehensive loss of CNY 47,235,805.90 in the prior period[34] - The basic and diluted earnings per share were both CNY 0.0006, a decline from CNY -0.0253 in the previous period[34] Cash Flow and Liquidity - The net cash flow from operating activities was ¥18,991,307.39, an increase of 68.76% year-on-year[6] - The cash inflow from operating activities totaled CNY 734,705,408.71, an increase from CNY 686,002,024.19 year-over-year[39] - The net cash flow from operating activities was CNY 32,049,044.25, up from CNY 18,991,307.39 in the prior year[39] - The net cash flow from investing activities was CNY -87,667,688.29, compared to CNY -60,508,581.39 in the previous period[41] - The net cash flow from financing activities was CNY 19,900,905.55, an increase from CNY 3,803,312.23 year-over-year[41] - The ending cash and cash equivalents balance was CNY 1,955,382,853.56, down from CNY 105,662,590.55 in the previous period[41] - The company reported a net increase in cash and cash equivalents of CNY -35,717,738.49, compared to a decrease of CNY -37,713,962.02 in the prior year[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,690,205,812.98, reflecting a growth of 1.29% from the end of the previous year[6] - The company's total assets increased to ¥6,776,359,687.06, compared to ¥6,690,205,812.98 in the previous period, marking a growth of 1.3%[28] - Total liabilities rose to ¥5,187,895,987.32, up from ¥5,104,155,707.98, indicating an increase of 1.6%[28] - The company's current assets total 3,029,966,838.82 RMB, slightly increasing from 3,023,848,238.36 RMB at the beginning of the year[22] - The cash and cash equivalents amount to 1,998,186,964.55 RMB, down from 2,033,160,168.10 RMB at the beginning of the year[22] - Accounts receivable increased to 616,533,876.71 RMB from 557,668,826.95 RMB[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,976[13] - The largest shareholder, Que Wenbin, holds 25.61% of the shares, totaling 477,639,999 shares[13] - The top ten shareholders include state-owned and private entities, with significant stakes held by Sichuan Industrial Revitalization Development Investment Fund and Northeast Securities[13] - The company reported a total of 475,687,230 shares under pledge, indicating potential liquidity concerns[13] Operational Changes and Risks - The company has entered the execution phase of its restructuring plan after the court's approval on April 22, 2022[21] - The company faces a risk of bankruptcy if the restructuring plan is not successfully executed[21] - The stock is under "delisting risk warning" and continues to be traded under the name "*ST Hengkang"[21] Expenses - Financial expenses increased by 66.51% to ¥36,557,171.98, primarily due to higher interest from acquisition funds and subsidiary borrowings[9] - The company recorded a decrease in non-operating income by 73.09%, amounting to ¥1,363,790.60 in the previous year[9] - The cash paid for the purchase of fixed assets increased by 44.84% to ¥87,827,688.29, indicating a rise in capital expenditures[12] - The company reported a decrease in sales expenses to ¥43,985,875.41 from ¥54,509,945.31, a reduction of 19.4%[31] - Research and development expenses were not specified, but the company continues to invest in innovation[31] Interest Income - The company reported a significant increase in interest income, which rose by 808.53% to ¥1,510,591.01 due to increased interest from restructured investments[9]

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven "big health" industry model, focusing on both medical services and pharmaceutical manufacturing [28]. - The company is focusing on expanding its services in response to the increasing healthcare demands driven by aging population and chronic diseases [44]. - The management highlighted the ongoing healthcare reforms as both an opportunity and a challenge for the company's future growth [44]. - The company focuses on a dual-driven strategy of medical services and pharmaceutical manufacturing, enhancing its competitive edge in the healthcare industry [52]. - The company aims to strengthen its regional medical center status by enhancing specialty construction and has received various hospital accreditation achievements in 2021 [63]. - The company is focusing on specialized capacity building in hospitals to enhance competitiveness in regional healthcare development [119]. - The company is committed to enhancing the capabilities of county-level medical services and improving the primary healthcare system [49]. - The company plans to add nearly 2,000 new hospital beds within two years, increasing total bed capacity to 10,000, significantly enhancing operational scale and profitability [119]. Financial Performance - The company's operating revenue for 2021 was ¥3,016,070,733.20, representing a 7.49% increase compared to ¥2,805,895,494.80 in 2020 [30]. - The net profit attributable to shareholders for 2021 was -¥371,431,516.93, a significant decline of 610.96% from -¥52,243,830.15 in 2020 [30]. - The net cash flow from operating activities was ¥277,294,763.28, a slight decrease of 2.29% from ¥283,796,318.85 in 2020 [30]. - The basic and diluted earnings per share for 2021 were -¥0.1991, reflecting a 611.07% decrease from -¥0.0280 in 2020 [30]. - Total assets at the end of 2021 were ¥6,690,205,812.98, an increase of 38.78% from ¥4,820,797,979.68 in 2020 [30]. - The company reported a quarterly operating revenue of ¥791,769,762.57 in Q4 2021, with a total annual revenue of ¥3,016,070,733.20 [36]. - The net profit attributable to shareholders in Q4 2021 was -¥312,357,886.43, contributing to the overall annual loss [36]. - The company experienced a significant increase in non-operating income, with government subsidies amounting to ¥10,098,941.29 in 2021 [40]. Governance and Compliance - The company has established a governance structure that complies with regulatory requirements, ensuring effective decision-making and accountability [129]. - The company has conducted three shareholder meetings during the reporting period, adhering to legal and regulatory standards [130]. - The company maintains complete independence from its controlling shareholders in terms of business operations, assets, personnel, and finance, ensuring no competitive relationship or dependency exists [135]. - The company has established a robust internal audit system with dedicated personnel to oversee internal controls, expenses, and asset management [135]. - The company has a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders [135]. - The company has implemented a transparent investor relations management system to facilitate communication with stakeholders [135]. - The company has recognized the need for better management of fixed asset investments, particularly regarding construction projects that have been stalled since 2019 [195]. Restructuring and Future Plans - The company has entered a restructuring plan execution phase after the court approved the plan, but faces bankruptcy risks if the plan is not executed smoothly [7][9]. - The company is currently in the execution phase of its restructuring plan, having reduced the board of directors from 9 to 5 members, with plans to complete the restructuring before holding further board elections [197]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves for the fiscal year [10]. - The company will firmly promote the long-term strategy of health business in 2022, actively responding to the challenges of population aging and imbalanced medical supply [115]. - The company will increase investment in the technical and research capabilities of medical institutions, enhancing the R&D strength of traditional Chinese medicine and the scale advantages of medical institutions [115]. - The company plans to expand the production scale of "Duyiwei" and enhance annual sales revenue, considering integration through external mergers and acquisitions [118]. Human Resources and Management - The total number of employees at the end of the reporting period was 7,622, with 5,158 being technical staff [174]. - The company has a total of 212 retired employees who require financial support [174]. - The company has undergone significant management changes, with multiple resignations and appointments aimed at meeting development needs [146]. - The management team includes experienced professionals with backgrounds in finance, healthcare, and management [150][151]. - The company is addressing human resource risks by focusing on attracting and retaining high-quality medical and management talent [124]. Market and Product Development - The company has over 36 pharmaceutical products, including 8 exclusive products nationwide and 20 products listed in the medical insurance catalog [52]. - The company's main product, "Duyiwei Capsules," has been included in the National Essential Medicines List, which is expected to positively impact market prospects [124]. - The company is exploring new high-end domestic medical services and innovative biopharmaceutical research and market operations [55]. - The company is committed to developing new technologies and products to meet market demands [154]. - Future guidance indicates a focus on strategic acquisitions and partnerships to bolster growth [148]. Risks and Challenges - The company emphasizes the importance of risk awareness among investors regarding future operational plans and profitability forecasts [6]. - The company faces potential risks from policy changes in healthcare reform, which could impact operations [122]. - The company has acknowledged issues with accounts receivable, particularly with a significant amount overdue for more than one year, reflecting insufficient collection efforts [194].